UNSPSC 51144105: Amfepramone hydrochloride

This classification denotes a cns stimulant and anorexiant with the molecular formula C13H19NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19V2PL39NG, chemically known as 1-propanone, 2-(diethylamino)-1-phenyl- but more generally known as amfepramone hydrochloride, which bears US NIH Compound Identifier 7029. European Medicines Agency schedules Amfepramone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00434MIG.

Most nations, for tariff and trade purposes, schedule amfepramone hydrochloride under HS 29223100. SMILES: CCN(CC)C(C)C(=O)C1CCCCC1.CL.

UNSPSC 51144105 Amfepramone hydrochloride is a Commodity code that captures pharmaceutical products, but the recent state and local activity under this code does not align with its nominal scope. The single recent opportunity posted to state and local procurement channels — Seminole County, Florida's IFB for naloxone and drug deactivation systems — involves naloxone (an opioid antagonist) and related harm-reduction equipment rather than amfepramone (a sympathomimetic amine). State and local procurement offices appear to use this code inconsistently or apply it to a broader class of pharmaceutical and medical supplies than the code's name suggests. Issuing bodies sourcing under this code include county health agencies and likely related public health departments, though the recent-opportunities block shows limited activity.

Seminole County, Florida is the only jurisdiction with a recent opportunity. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building at 520 W. Lake Mary Blvd, Sanford, FL 32771. The response deadline was July 26, 2023. The contract carries a two-year initial term with an optional one-year renewal, and vendors must provide unit pricing, comply with drug-free workplace certification and E-Verify requirements, and maintain workers' compensation and liability insurance. The procurement does not explicitly designate set-asides for disadvantaged enterprises. The mismatch between the code's nominal pharmaceutical scope and the actual work being solicited suggests this code sees minimal relevant recent activity in state and local procurement.